Remarkably, the effect of IFNβ therapy on the proportions of TB cells differed according to HCMV serostatus, observing an increase in treated HCMV(+) MS patients but not in seronegative cases (Fig. 3b). The gene discussed is IFNB1; the disease is myeloid sarcoma.